Purple Biotech Ltd.
Symbol: PPBT
NASDAQ
0.67
USDDzisiejsza cena rynkowa
-0.6555
Wskaźnik P/E
0.0000
Wskaźnik PEG
17.38M
Kapitalizacja MRK
- 0.00%
Rentowność DIV
Purple Biotech Ltd. (PPBT) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 15.4 | 32.1 | 47.2 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 0.9 | 17.1 | 36.3 | |||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 0.4 | 1.1 | 1.3 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 15.8 | 33.3 | 48.5 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0.5 | 0.7 | 0.9 | |||||||||||
balance-sheet.row.goodwill | 0 | 28 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 20.7 | 20.5 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 28 | 20.7 | 20.5 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0.2 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0.2 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 28.5 | 21.4 | 21.7 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 0 | 44.3 | 54.6 | 70.2 | |||||||||||
balance-sheet.row.account-payables | 0 | 3.5 | 2.1 | 1.5 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 0.2 | 0.2 | 0.2 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0.2 | 0.3 | 0.6 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 3.5 | 4.7 | 2.6 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 2.8 | 0.5 | 0.8 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0.2 | 0.5 | 0.7 | |||||||||||
balance-sheet.row.total-liab | 0 | 10 | 7.5 | 5.1 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | 0 | -137.5 | -117.6 | -95.9 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 38.5 | 10.1 | 8.8 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 133.2 | 154.4 | 152 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 34.2 | 46.9 | 64.8 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 44.3 | 54.6 | 70.2 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0.1 | 0.2 | 0.3 | |||||||||||
balance-sheet.row.total-equity | 0 | 34.3 | 47.1 | 65.1 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 0.9 | 17.1 | 36.5 | |||||||||||
balance-sheet.row.total-debt | 0 | 0.4 | 0.5 | 0.7 | |||||||||||
balance-sheet.row.net-debt | 0 | -14.1 | -14.5 | -10.1 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -19.9 | -21.8 | -17.8 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0.2 | 0.2 | 0.2 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | -0.8 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | 1.9 | 2.4 | 2.1 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | 0.3 | 3.3 | 0.6 | |||||||||||
cash-flows.row.account-receivables | 0 | 0.2 | 0.3 | -0.3 | |||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0.6 | |||||||||||
cash-flows.row.account-payables | 0 | 1.3 | 0.8 | 0.3 | |||||||||||
cash-flows.row.other-working-capital | 0 | -1.2 | 2.1 | 0 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | -0.9 | -0.8 | -0.1 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.2 | -0.1 | |||||||||||
cash-flows.row.acquisitions-net | 0 | -3.5 | 0 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 16.7 | 19.8 | 13.2 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0.3 | 0.4 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 13.1 | 19.9 | 13.4 | |||||||||||
cash-flows.row.debt-repayment | 0 | -0.2 | -0.2 | -0.2 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 5.7 | 1.5 | 0.6 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 0 | -0.9 | -0.2 | 1.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 5.5 | 1.1 | 1.5 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0.1 | -0.2 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | -0.5 | 4.1 | -0.4 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 14.5 | 15 | 10.9 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 15 | 10.9 | 11.2 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | -19.2 | -16.7 | -15.1 | |||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.2 | -0.1 | |||||||||||
cash-flows.row.free-cash-flow | 0 | -19.2 | -17 | -15.2 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | -0.9 | -0.3 | |||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0.2 | 0.2 | 0.2 | |||||||||||
income-statement-row.row.gross-profit | 0 | -0.2 | -1.1 | -0.6 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 0 | 22.1 | 22.6 | 17.9 | |||||||||||
income-statement-row.row.cost-and-expenses | 0 | 22.3 | 22.6 | 17.9 | |||||||||||
income-statement-row.row.interest-income | 0 | 0.5 | 1 | 0.3 | |||||||||||
income-statement-row.row.interest-expense | 0 | 2.2 | 0.1 | 0.2 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 2.3 | 0.8 | 0.1 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | 0 | 2.3 | 0.8 | 0.1 | |||||||||||
income-statement-row.row.interest-expense | 0 | 2.2 | 0.1 | 0.2 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0.2 | 1.2 | 0.6 | |||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 0 | -22.3 | -22.6 | -17.9 | |||||||||||
income-statement-row.row.income-before-tax | 0 | -20 | -21.8 | -17.8 | |||||||||||
income-statement-row.row.income-tax-expense | 0 | -0.1 | -0.9 | 0.6 | |||||||||||
income-statement-row.row.net-income | 0 | -19.9 | -20.8 | -18.5 |
Często zadawane pytania
Ile wynosi Purple Biotech Ltd. (PPBT) aktywów ogółem?
Purple Biotech Ltd. (PPBT) całkowite aktywa to 44302000.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to N/A.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.000.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to -0.807.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to 0.000.
Jaki jest całkowity przychód firmy?
Całkowity przychód to 0.000.
Co to jest Purple Biotech Ltd. (PPBT) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi -19880000.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 351000.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 22072000.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 0.000.